Hoffmann-La Roche AG

42 articles about Hoffmann-La Roche AG

• COLUMVI® (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  3/25/2023

  Hoffmann-La Roche Limited announced that on March 24, 2023 Health Canada authorized COLUMVI® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma, who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy.

• Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

  11/24/2022

  Hoffmann-La Roche Limited is pleased to announce that on November 14, 2022, Health Canada has authorized POLIVY® in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high grade B-cell lymphoma, Epstein-Barr virus-positive DLBCL NOS, and T-cell/histiocyte rich LBCL.

• TECENTRIQ® (atezolizumab) Receives CADTH Reimbursement Recommendations for the adjuvant treatment of early-stage Non-Small Lung Cell Cancer (NSCLC) and the treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  10/5/2022

  Hoffmann-La Roche Limited announced that the Canadian Agency for Drugs and Technologies in Health pan-Canadian Oncology Drug Review Expert Review Committee has issued two final recommendations for TECENTRIQ®.

• Health Canada authorizes VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

  6/1/2022

  Hoffmann-La Roche Limited is pleased to announce that Health Canada authorized VABYSMO® for the treatment of neovascular age-related macular degeneration and diabetic macular edema, two of the leading causes of vision loss among Canadians.

• Roche Canada Announces Collaboration to Improve Access to Personalized Healthcare with Real World Evidence

  5/28/2021

  BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate cost-effective access to targeted treatments for cancer patients

• City of Mississauga Applauds Roche Canada Jobs Investment in Life Sciences Industry

  10/19/2020

  Hoffmann-La Roche Limited has announced a major jobs investment into Ontario's life sciences industry that will bring up to 500 highly skilled and specialized full-time positions to the City of Mississauga.

• Roche Canada Announces Winners of COVID-19 Open Innovation Challenge

  6/2/2020

  Program will fund 11 unique solutions for challenges posed by COVID-19 from Canadians across the country

• Roche Canada Launches Data Science Coalition to Advance COVID-19 Solutions - April 16, 2020

  4/16/2020

  Coalition created a publicly available centralized repository to enhance research

• Roche Canada Launches Data Science Coalition to advance COVID-19 solutions

  4/8/2020

  Coalition created a publicly available centralized repository to enhance research

• Roche Canada establishes COVID-19 Open Innovation Challenge

  3/31/2020

  Hoffmann-La Roche Limited is pleased to announce the launch of the COVID-19 Open Innovation Challenge to encourage Canadians to help develop solutions to the challenges we face from the COVID-19 pandemic.

• Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)

  11/28/2019

  Data show patients had a 50% reduction in risk of recurrence compared to treatment with Herceptin® (trastuzumab) after surgery2

• Hoffmann-La Roche AG Release: Health Canada Approves TECENTRIQ (Atezolizumab) For Patients With Locally Advanced And Metastatic Bladder Cancer

  4/18/2017

• ZIOPHARM, Inc. Elects George B. Abercrombie, former CEO of Hoffmann-La Roche AG, to Board of Directors

  4/6/2010

• AstraZeneca AB, Merck & Co., Inc., Novartis AG, H. Lundbeck A/S, Hoffmann-La Roche AG, And GlaxoSmithKline Explore Advances in Solubility, Amorphous Forms and Lipid-Based Formulation of Drugs

  2/4/2010

• Hoffmann-La Roche AG (JOBS) Says New Data Confirm Mabthera, Actemra Work

  10/27/2008

• Hoffmann-La Roche AG's PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered "Cured"

  5/22/2007

• Roche and Synosis Therapeutics Announce Partnership To Explore Potential Of Five Compounds Targeting The Central Nervous System

  1/4/2007

• Hoffmann-La Roche AG Release: Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit In Patients With Advanced Breast Cancer

  12/15/2006

• ArQule, Inc. Initiates Phase 1 Trial With ARQ 171, Provides Enrollment Update On ARQ 501 And ARQ 197

  12/6/2006

• Roche And InterMune, Inc. Sign $530M Agreement To Collaborate On The Research, Development And Commercialization Of Hepatitis C Protease Inhibitors

  10/17/2006